Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duality BiotherapeuticsHKSE:09606 -1.61%9 Days Payable is 351.21 as of Jun. 2026, which is 124% above its 10-year median of 156.63. GuruFocus rates HKSE:09606 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 707 Biotechnology companies, Duality Biotherapeutics ranks better than 70.3% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics Days Payable Chart
Duality Biotherapeutics Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Days Payable
25,422.97
154.19
140.58
205.17
Duality Biotherapeutics Semi-Annual Data
Jun25
Dec25
Jun26
Days Payable
148.86
208.08
351.21
HKSE:09606 vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Duality Biotherapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Duality Biotherapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics (HKSE:09606) has a Days Payable of 351.21 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Duality Biotherapeutics and its competitors. This is 124% above median its historical median of 156.63. Over the past decade, Duality Biotherapeutics' Days Payable has ranged from 143.82 to 276.56. According to the industry distribution chart, Duality Biotherapeutics ranks #210 out of 707 companies in the Biotechnology industry, placing it in the top 29.7%.
Is Duality Biotherapeutics' Days Payable too high?
Duality Biotherapeutics' current Days Payable of 351.21 is 124% above median its 10-year median of 156.63. Over the past 10 years, this metric has ranged from a low of 143.82 to a high of 276.56. The Biotechnology industry median Days Payable is 111.24. Duality Biotherapeutics' value of 351.21 is 215.7% above this industry median. Based on the distribution chart, Duality Biotherapeutics ranks #210 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Duality Biotherapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #210 out of 707 companies for Days Payable. This puts Duality Biotherapeutics in the upper half of its industry. The industry median Days Payable is 111.24. Duality Biotherapeutics' value of 351.21 is 215.7% above this benchmark. Historically, Duality Biotherapeutics' own Days Payable has ranged from 143.82 to 276.56 over the past decade. While the company's 10-year median is 156.63 vs. the industry median of 111.24, Duality Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duality Biotherapeutics's current Days Payable of 351.21 is 215.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Duality Biotherapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duality Biotherapeutics's current Days Payable is 351.21, which is 124% above median its own 10-year median of 156.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (HKSE:09606) has a current Days Payable of 351.21. The current Days Payable is 351.21, which is 124% above median its 10-year median of 156.63 and 215.7% above the Biotechnology industry median of 111.24. Duality Biotherapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Duality Biotherapeutics (HKSE:09606), the current Days Payable is 351.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
9GF Score
Get the complete analysis for HKSE:09606
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:09606 has been successfully added to your 
